Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Keating

Showing results (141-150 of 188) with videos related to

Pageof 19
Sort By:
Leukemia Research|March 21, 2006
Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's diseaseMaher Albitar, Julie M Vose, Marcella M Johnson, et al.
British Journal of Haematology|June 16, 2016
Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trialDai Chihara, Hagop Kantarjian, Susan O'Brien, et al.
Cancer|December 12, 2003
Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic dataHagop M Kantarjian, Susan O'Brien, Jorge Cortes, et al.
British Journal of Haematology|February 13, 2003
Plasma interleukin 8 level predicts for survival in chronic lymphocytic leukaemiaWilliam G Wierda, Marcella M Johnson, Kim-Anh Do, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2004
Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controlsHagop Kantarjian, Susan O'Brien, Jorge Cortes, et al.
Blood|August 9, 2011
Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemiaFarhad Ravandi, Susan O'Brien, Jeffrey Jorgensen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 2009
Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatmentWilliam G Wierda, Susan O'Brien, Xuemei Wang, et al.
Cancer|December 15, 2005
A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimensWilliam Wierda, Susan O'brien, Stefan Faderl, et al.
Addiction (Abingdon, England)|December 3, 2021
The geography of sobriety checkpoints and alcohol-impaired drivingChristopher N Morrison, Muhire Kwizera, Qixuan Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2009
Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasmsFarhad Ravandi, Ahmed Aribi, Susan O'Brien, et al.
Pageof 19

Showing results (141-150 of 188) with videos related to

Sort By:
Pageof 19
Leukemia Research|March 21, 2006
Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's diseaseMaher Albitar, Julie M Vose, Marcella M Johnson, et al.
British Journal of Haematology|June 16, 2016
Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trialDai Chihara, Hagop Kantarjian, Susan O'Brien, et al.
Cancer|December 12, 2003
Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic dataHagop M Kantarjian, Susan O'Brien, Jorge Cortes, et al.
British Journal of Haematology|February 13, 2003
Plasma interleukin 8 level predicts for survival in chronic lymphocytic leukaemiaWilliam G Wierda, Marcella M Johnson, Kim-Anh Do, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2004
Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controlsHagop Kantarjian, Susan O'Brien, Jorge Cortes, et al.
Blood|August 9, 2011
Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemiaFarhad Ravandi, Susan O'Brien, Jeffrey Jorgensen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 2009
Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatmentWilliam G Wierda, Susan O'Brien, Xuemei Wang, et al.
Cancer|December 15, 2005
A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimensWilliam Wierda, Susan O'brien, Stefan Faderl, et al.
Addiction (Abingdon, England)|December 3, 2021
The geography of sobriety checkpoints and alcohol-impaired drivingChristopher N Morrison, Muhire Kwizera, Qixuan Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2009
Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasmsFarhad Ravandi, Ahmed Aribi, Susan O'Brien, et al.
Pageof 19